Table 3. Number of estimated and notified MDR-TB and RR-TB cases, proportion notified among estimated MDR-TB and RR-TB cases and number and proportion of MDR-TB and RR-TB cases enrolled in treatment by selected country,* WHO Western Pacific Region, 2013†.
| Countries and areas | Estimated | Notified | Percentage notified among estimated | Enrolled in treatment | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| New | Prev | Total | New | Prev | Total‡ | New | Prev | Total | |||||||||
| N | (95% CI) | N | (95% CI) | N | (95% CI) | N | (95% CI) | N | (95% CI) | N | (95% CI) | n | % among detected | ||||
| Australia | 16 | (8–27) | 1 | (0–7) | 17 | (8–26) | 13 | 3 | 24 | 81 | (48–144) | 300 | (43–NA) | 141 | (92–300) | 22 | 92 |
| Brunei Darussalam | 1 | (0–6) | 0 | (0–3) | 1 | (0–3) | 1 | 0 | 1 | 100 | (17–NA) | – | (0–NA) | 100 | (33–NA) | 0 | 0 |
| Cambodia | 320 | (270–580) | 180 | (68–370) | 510 | (270–740) | – | – | 121 | – | (NA–NA) | – | (NA–NA) | 24 | (16–45) | 121 | 100 |
| China | 45 000 | (48 000–55 000) | 9200 | (7800–11 000) | 54 000 | (48 000–61 000) | 1612 | 2571 | 4183 | 4 | (3–5) | 28 | (23–33) | 8 | (7–9) | 2184 | 52 |
| Hong Kong Special Administrative Region | 34 | (26–52) | 9 | (3–20) | 43 | (26–59) | 28 | 7 | 35 | 82 | (54–133) | 78 | (35–233) | 81 | (59–135) | 22 | 63 |
| Macao Special Administrative Region | 7 | (4–16) | 4 | (1–10) | 11 | (4–18) | 6 | 3 | 10 | 86 | (38–300) | 75 | (30–300) | 91 | (56–250) | 8 | 80 |
| Cook Islands | 0 | (0–1) | 0 | (0–0) | 0 | (0–1) | 0 | 0 | 2 | – | (0–NA) | – | (NA–NA) | NA | (200–NA) | 0 | 0 |
| Japan | 110 | (150–160) | 100 | (72–130) | 200 | (150–560) | 42 | 22 | 64 | 38 | (26–67) | 22 | (17–31) | 32 | (25–43) | – | – |
| Lao People’s Democratic Republic | 160 | (160–230) | 65 | (56–75) | 220 | (160–290) | 0 | 7 | 7 | 0 | (0–0) | 11 | (9–12) | 3 | (2–4) | 4 | 57 |
| Malaysia | 19 | (0–120) | 0 | (0–340) | 19 | (0–57) | 80 | 5 | 277 | 421 | (67–NA) | NA | (1–NA) | 1458 | (486–NA) | 49 | 18 |
| Marshall Islands | 2 | (0–9) | 0 | (0–5) | 2 | (0–5) | 1 | 0 | 1 | 50 | (11–NA) | – | (0–NA) | 50 | (20–NA) | 1 | 100 |
| Mongolia | 33 | (210–59) | 210 | (180–240) | 240 | (210–280) | 64 | 177 | 257 | 194 | (108–400) | 84 | (74–98) | 107 | (92–122) | 192 | 75 |
| New Zealand | 1 | (0–5) | 2 | (0–5) | 3 | (0–6) | 1 | 1 | 3 | 100 | (20–NA) | 50 | (20–NA) | 100 | (50–NA) | 2 | 67 |
| Palau | 0 | (0–3) | 0 | (0–0) | 0 | (0–3) | 0 | 0 | 1 | – | (0–NA) | – | (NA–NA) | NA | (33–NA) | 0 | 0 |
| Papua New Guinea | 560 | (890–800) | 570 | (480–650) | 1100 | (890–1400) | – | – | 119 | – | (NA–NA) | – | (NA–NA) | 11 | (8–13) | 145 | 122 |
| Philippines | 4400 | (6900–6000) | 4100 | (3000–5500) | 8500 | (6900–10 000) | 10 | 1349 | 3962 | <1 | (<1–<1) | 33 | (25–45) | 47 | (40–57) | 2262 | 57 |
| Republic of Korea | 780 | (1600–980) | 1200 | (850–1600) | 1900 | (1600–2300) | 466 | 518 | 984 | 60 | (48–78) | 43 | (32–61) | 52 | (43–62) | 951 | 97 |
| Singapore | 17 | (9–30) | 3 | (0–12) | 20 | (9–31) | 14 | 4 | 18 | 82 | (47–175) | 133 | (33–NA) | 90 | (58–200) | 15 | 83 |
| Viet Nam | 3000 | (4100–4100) | 2100 | (1500–2600) | 5100 | (4100–6100) | 40 | 997 | 1204 | 1 | (<1–2) | 47 | (38–66) | 24 | (20–29) | 948 | 79 |
| Western Pacific Region | 53 000 | (47 000–75 000) | 18 000 | (15 000–21 000) | 71 000 | (47 000–94 000) | 2379 | 5664 | 11 153 | 4 | (3–8) | 31 | (27–38) | 16 | (12–24) | 6926 | 62 |
CI, confidence interval; MDR-TB, multidrug-resistant tuberculosis; NA, not applicable; Prev, previously treated tuberculosis; RR-TB, rifampicin-resistant tuberculosis.
* Countries that reported at least one MDR-TB case in 2013.
† All columns except estimates include RR-TB cases confirmed by Xpert only. Total MDR-TB cases detected included cases among extrapulmonary and from samples taken more than 2 weeks after start of treatment.
‡ Total column includes cases with treatment history unavailable.